Filing Details
- Accession Number:
- 0001349929-17-000038
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-05-25 16:54:55
- Reporting Period:
- 2017-05-23
- Filing Date:
- 2017-05-25
- Accepted Time:
- 2017-05-25 16:54:55
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1349929 | Cancer Genetics Inc | CGIX | Services-Medical Laboratories (8071) | 043462475 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1698874 | Igor Gitelman | 201 Route 17 N. 2Nd Floor Rutherford NJ 07070 | Chief Accounting Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2017-05-23 | 937 | $2.50 | 937 | No | 4 | M | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Disposition | 2017-05-23 | 937 | $4.02 | 0 | No | 4 | S | Direct | |
| Common Stock, Par Value $0.0001 Per Share | Acquisiton | 2017-05-25 | 937 | $3.95 | 937 | No | 4 | P | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | P | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock, Par Value $0.0001 Per Share | Stock Option (right to buy) | Disposition | 2017-05-23 | 937 | $0.00 | 937 | $2.50 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,063 | 2027-02-22 | No | 4 | M | Direct |
Footnotes
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.025 to $4.01, inclusive. The reporting person undertakes to provide Cancer Genetics, Inc., any security holder of Cancer Genetics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (1) to this Form 4.
- The shares underlying the option shall vest in 48 equal monthly installments commencing on the date of grant until fully vested, provided that the reporting person remains a service provider to Cancer Genetics, Inc. through each applicable vesting period.
Billionaire Hedge Funds
